Minerva Neurosciences, Inc.
Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
WALTHAM, Mass., 2017-03-21 21:10 CET (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today announced the recent exercise of warrants held by certain institutional stockholders in connection with a private placement that took place in March 2015, as well as a purchase of common stock completed on the open market by the chairman of Minerva’s board of directors.
Since December 31, 2016, warrants with respect to a total of 1,621,073 shares have been exercised by such stockholders at an exercise price of $5.772 per share. As a result, the Company has received approximately $9.4 million in proceeds since December 31, 2016. The warrants issued in connection with the private placement expired on March 20, 2017.
Separately, 50,000 shares of Minerva common stock have been purchased by Marc Beer, chairman of the board of directors of Minerva. These purchases took place in multiple transactions at prices ranging from $7.65 to $8.45 and have been reflected in a Form 4 filing with the Securities and Exchange Commission on March 21, 2017.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visitwww.minervaneurosciences.com.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
SEMAFO Inc.22.3.2018 12:01 | pressemeddelelse
SEMAFO: Construction of Boungou Mine 87% Complete
3Gtms21.3.2018 15:02 | pressemeddelelse
3Gtms Positioned in the Niche Players Quadrant of the Gartner Magic Quadrant for Transportation Management Systems
Addivant21.3.2018 14:39 | pressemeddelelse
Addivant Announces Price Increases on Hindered Amine Light Stablizers
VistaJet Ltd21.3.2018 14:19 | pressemeddelelse
VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour
Boyden21.3.2018 06:04 | pressemeddelelse
Boyden Focuses on Expansion in Nordic Region
Institutional Investor News21.3.2018 06:04 | pressemeddelelse
Intesa Sanpaolo, Iberdrola, and Ryanair Among Big Winners on Institutional Investor's 2018 All-Europe Executive Team Rankings
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum